Vivoryon has extended the trial protocol through the inclusion of exploratory parameters and plans to enroll patients in selected study sites in Denmark, Germany and the […]
HALLE (SAALE)/MUNICH, Germany, 3 March 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that its management will be presenting at and attending the […]
HALLE (SAALE), Germany and Herlev, Denmark, 14 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) and Nordic Bioscience, announced today an agreement to collaborate […]
HALLE (SAALE), Germany, 7 January 2020 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that the company is scheduled to attend the J.P. Morgan […]
HALLE (SAALE), Germany, 20 December 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), announced today that the company has been included in the AScX index as of […]
HALLE (SAALE), Germany, 28 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today its third quarter business update for the period ending September […]
HALLE (SAALE), Germany, 27 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN: DE0007921835), announced today that management of Vivoryon Therapeutics will attend the CTAD […]
HALLE (SAALE), Germany, 21 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), will publish its third quarter financial results and a business update for the period […]
HALLE (SAALE), Germany, 4 November 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), announced today that the company is scheduled to attend and present at upcoming conferences […]